Trial Profile
A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 03 Oct 2006 Status change
- 04 Nov 2005 New trial record.